Litoxetine (IXA-001)
Undisclosed Urogenital Disorder (likely female)
Phase 2Active
Key Facts
About IXALTIS
IXALTIS is a private, clinical-stage biotech developing therapies for urogenital diseases with high unmet medical need. Its strategy centers on in-licensing and repurposing previously developed clinical compounds, with its lead asset, Litoxetine (IXA-001), currently in Phase II for an unspecified urogenital indication. The company is backed by a specialized team, a world-class scientific advisory board, and has secured Series A financing from investor IXO Private Equity. Its model aims to de-risk and accelerate development by building on existing clinical data.
View full company profile